Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Ferring B.V. maintains a patent portfolio with 4 pending office actions, all situated within the Biotechnology & Pharmaceuticals technology area. The prosecution of these matters is distributed across 4 distinct examiners and 4 distinct art units. This distribution suggests a variety of technical challenges across the pending applications.
DICKENS, AMELIA NICOLE is the busiest examiner for the portfolio, currently handling 1 pending office action. Because the total volume of 4 pending actions is spread among 4 examiners, no individual holds more than 1 action. Each of the 4 distinct art units likely presents unique examination standards that Ferring B.V. must navigate simultaneously.
The presence of 4 distinct art units indicates that the Biotechnology & Pharmaceuticals filings cover several specialized sub-sectors. Strategy should be tailored to the specific examiner, as DICKENS, AMELIA NICOLE and the other examiners each manage a pending action. This distribution requires monitoring separate prosecution tracks within the broader technology area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKENS, AMELIA NICOLE | 1 | 47.6% | +21.1% |
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
| BRADLEY, CHRISTINA | 1 | 62.6% | +33.3% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266159 | COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION | BRADLEY, CHRISTINA | 22d |
| 18556625 | BACTERIOPHAGE THERAPY AGAINST ADHERENT-INVASIVE ESCHERICHIA COLI | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266159 | COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION | BRADLEY, CHRISTINA | 22d |
| 18570436 | BACTERIOPHAGES AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI | DICKENS, AMELIA NICOLE | — |
| 18556625 | BACTERIOPHAGE THERAPY AGAINST ADHERENT-INVASIVE ESCHERICHIA COLI | SIFFORD, JEFFREY MARK | — |
| 18009469 | PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE | HOWARD, ZACHARY C | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1671 | 1 |
| 1654 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18570436 | BACTERIOPHAGES AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI | DICKENS, AMELIA NICOLE | 1645 | §112 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18556625 | BACTERIOPHAGE THERAPY AGAINST ADHERENT-INVASIVE ESCHERICHIA COLI | SIFFORD, JEFFREY MARK | 1671 | §103§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18266159 | COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION | BRADLEY, CHRISTINA | 1654 | §101§102§103 | Final Rejection | 22d | Pending | Jun 08, 2023 |
| 18009469 | PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE | HOWARD, ZACHARY C | 1674 | §103Other | Non-Final OA | — | Pending | Dec 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial